Not all sufferers with CLL have to have therapy. Despite all current improvements, the iwCLL however endorses watchful observation for people with asymptomatic disease.86 This recommendation is based on at the least two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).Are